Covered recipient · General Payments record
SANT CHAWLA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$3,030.14
103 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,694.91 | 99 |
| Education | $335.23 | 4 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SANT CHAWLA
NPI 1508868837 · CMS profile ID 249452
SANTA MONICA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508868837?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SANT CHAWLA, NPI 1508868837, CMS profile ID 249452. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508868837?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SANT CHAWLA, NPI 1508868837, CMS profile ID 249452. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508868837?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SANT CHAWLA, NPI 1508868837, CMS profile ID 249452, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508868837?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
103 matching records · $3,030.14 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 103.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $27.09 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233232024 | CMS |
| Deciphera Pharmaceuticals Inc. | $19.54 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235958543 | CMS |
| Daiichi Sankyo Inc. | $20.86 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197080713 | CMS |
| Daiichi Sankyo Inc. | $0.59 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197081279 | CMS |
| SpringWorks Therapeutics, Inc. | $0.22 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232161131 | CMS |
| SpringWorks Therapeutics, Inc. | $17.42 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232161133 | CMS |
| Incyte Corporation | $27.22 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225987535 | CMS |
| Janssen Biotech, Inc. | $143.75 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174823766 | CMS |
| SpringWorks Therapeutics, Inc. | $24.23 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232161129 | CMS |
| PFIZER INC. | $29.02 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229027106 | CMS |
| Ipsen Biopharmaceuticals, Inc | $25.36 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208828205 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.02 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215321387 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $27.96 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225492930 | CMS |
| Daiichi Sankyo Inc. | $27.38 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197062835 | CMS |
| Daiichi Sankyo Inc. | $0.82 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197063327 | CMS |
| Astellas Pharma US Inc | $30.78 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238635876 | CMS |
| Astellas Pharma US Inc | $3.04 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238635882 | CMS |
| Immunocore Limited | $34.37 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235825066 | CMS |
| Merck Sharp & Dohme LLC | $29.68 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238142622 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.26 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215340290 | CMS |
| SpringWorks Therapeutics, Inc. | $29.23 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232161127 | CMS |
| Novartis Pharmaceuticals Corporation | $17.10 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200124623 | CMS |
| PFIZER INC. | $32.54 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228943514 | CMS |
| PROGENICS PHARMACEUTICALS, INC. | $17.26 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245237557 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.53 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184842763 | CMS |
| ABBVIE INC. | $26.61 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201640999 | CMS |
| Daiichi Sankyo Inc. | $21.53 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197054123 | CMS |
| Daiichi Sankyo Inc. | $1.05 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197059323 | CMS |
| Daiichi Sankyo Inc. | $28.16 | 04/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197055521 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.70 | 03/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184842751 | CMS |
| ACCORD HEALTHCARE, INC. | $18.04 | 03/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248746047 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $19.26 | 03/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225492928 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.35 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215347626 | CMS |
| Novartis Pharmaceuticals Corporation | $27.79 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200124601 | CMS |
| Lilly USA, LLC | $27.46 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186903342 | CMS |
| Ipsen Biopharmaceuticals, Inc | $17.10 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208828203 | CMS |
| Gilead Sciences, Inc. | $30.30 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234436283 | CMS |
| Merck Sharp & Dohme LLC | $29.12 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238284931 | CMS |
| Daiichi Sankyo Inc. | $28.72 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197041631 | CMS |
| Novartis Pharmaceuticals Corporation | $17.89 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200124621 | CMS |
| SpringWorks Therapeutics, Inc. | $28.50 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232161125 | CMS |
| PFIZER INC. | $28.00 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228882847 | CMS |
| ARRAY BIOPHARMA INC | $26.15 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228867643 | CMS |
| Coherus Oncology, Inc. | $22.00 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235239145 | CMS |
| Janssen Biotech, Inc. | $28.22 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174827230 | CMS |
| Daiichi Sankyo Inc. | $28.72 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197050677 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.63 | 01/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184842727 | CMS |
| SpringWorks Therapeutics, Inc. | $38.98 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232161123 | CMS |
| Incyte Corporation | $28.02 | 01/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225986677 | CMS |
| Daiichi Sankyo Inc. | $24.47 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197072707 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $6,400.00 | 2 |
| PY2025 | Principal investigator | $929,442.37 | 100 |
| PY2024 | Principal investigator | $1,238,832.99 | 89 |
| PY2023 | Recipient | $1,270.00 | 2 |
| PY2023 | Principal investigator | $1,388,882.22 | 78 |
| PY2022 | Recipient | $940.00 | 1 |
| PY2022 | Principal investigator | $1,019,395.82 | 42 |
| PY2021 | Recipient | $388.51 | 2 |
| PY2021 | Principal investigator | $455,963.10 | 30 |
| PY2020 | Recipient | $2,460.36 | 4 |
| PY2020 | Principal investigator | $2,128,468.11 | 53 |
| PY2019 | Principal investigator | $3,640,139.13 | 33 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
102 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $46,130.90 | 12/18/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812338 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,195.00 | 12/18/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812354 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $157,320.00 | 12/18/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A P1,2 dose escal,expan to evaluate PYX-201 and Pembro in Adv solid tumors | No dispute reported | 06/30/2026 | 1232936250 |
| Principal investigator 1 | Epizyme, Inc. | $45,961.00 | 10/31/2025 | Non-covered Recipient Entity Oncology Center | A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | No dispute reported | 06/30/2026 | 1184282387 |
| Principal investigator 1 | Epizyme, Inc. | $45,961.00 | 10/31/2025 | Non-covered Recipient Entity Oncology Center | A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | No dispute reported | 06/30/2026 | 1184282389 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $1,567.00 | 10/03/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209069 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $1,899.00 | 10/03/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209071 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $624.00 | 10/03/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209073 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,988.90 | 08/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812398 |
| Principal investigator 1 | Servier BioInnovation | $15,000.00 | 08/06/2025 | Non-covered Recipient Entity Sarcoma Oncology Research Center | Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) | No dispute reported | 06/30/2026 | 1235974000 |
| Principal investigator 1 | Servier BioInnovation | $2,000.00 | 08/06/2025 | Non-covered Recipient Entity Sarcoma Oncology Research Center | Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) | No dispute reported | 06/30/2026 | 1235974004 |
| Recipient | PFIZER INC. | $3,200.00 | 08/01/2025 | Covered Recipient Physician | ONTORPACEPT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228803504 |
| Recipient | PFIZER INC. | $3,200.00 | 08/01/2025 | Covered Recipient Physician | ONTORPACEPT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228803508 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,307.99 | 07/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812330 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,581.10 | 07/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812332 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,717.40 | 07/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812334 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,108.00 | 07/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812336 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,761.90 | 07/08/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812396 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,168.00 | 07/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812352 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,205.90 | 06/26/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812328 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,806.00 | 06/16/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812326 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,893.40 | 06/16/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812350 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,940.40 | 06/12/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812394 |
| Principal investigator 1 | Amgen Inc. | $1,488.58 | 05/27/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER LLC | A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1246648039 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $2,400.00 | 05/23/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208919 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,096.00 | 05/16/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812318 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,644.00 | 05/16/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812320 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,128.00 | 05/16/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812322 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,096.00 | 05/16/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812324 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,547.50 | 05/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812348 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,346.00 | 05/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812390 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $37,038.00 | 05/15/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812392 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $54,982.00 | 05/14/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812388 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,195.80 | 05/13/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812316 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,692.00 | 05/13/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812382 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,865.00 | 05/13/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812384 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $37,038.00 | 05/13/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812386 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $588.00 | 05/09/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208921 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $140.00 | 05/09/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209023 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $395.00 | 05/09/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209025 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $4,873.00 | 05/09/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209027 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $588.00 | 05/09/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250209029 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,336.50 | 05/09/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812314 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,336.50 | 05/09/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812346 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,345.30 | 05/09/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812380 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,173.00 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812366 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $49,384.00 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812368 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,004.75 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812370 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,173.00 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812372 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,173.00 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812374 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,173.00 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812376 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,865.00 | 05/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812378 |
| Principal investigator 1 | Amgen Inc. | $27,017.00 | 05/02/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER LLC | A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1246648043 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,786.80 | 05/02/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812344 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,821.50 | 04/14/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812364 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,243.00 | 04/10/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812310 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,692.00 | 04/09/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812362 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,009.50 | 04/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812306 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,261.80 | 04/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812308 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.09 | 04/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812312 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207864 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207866 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207868 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207870 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207882 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207884 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207886 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250207888 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208925 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208927 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208929 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208931 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208933 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208935 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208937 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208939 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208941 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208943 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208945 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208969 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208971 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208973 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $437.50 | 03/28/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | Not supplied | No dispute reported | 06/30/2026 | 1250208975 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,764.00 | 03/26/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812304 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28,066.50 | 03/26/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812360 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,346.00 | 03/24/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812342 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,446.80 | 03/18/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812358 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,622.39 | 03/11/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812302 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,394.50 | 03/04/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812300 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,706.67 | 03/03/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812296 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $612.10 | 03/03/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812298 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.09 | 03/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812288 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $537.54 | 03/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812294 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,687.25 | 03/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812340 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,807.54 | 02/26/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812292 |
| Principal investigator 1 | SpringWorks Therapeutics, Inc. | $11,943.50 | 02/20/2025 | Non-covered Recipient Entity SARCOMA ONCOLOGY RESEARCH CENTER | NIR-DT-301 | No dispute reported | 06/30/2026 | 1232168422 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,719.00 | 02/07/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812282 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.09 | 02/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812286 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,078.30 | 01/22/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4 | No dispute reported | 06/30/2026 | 1220812280 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,961.60 | 01/06/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812284 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26,492.40 | 01/06/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma | No dispute reported | 06/30/2026 | 1220812356 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.09 | 01/01/2025 | Non-covered Recipient Entity Sarcoma Oncology Center | A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors | No dispute reported | 06/30/2026 | 1220812290 |